Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease hepatitis b
Phenotype C0079731|b-cell lymphoma
Sentences 5
PubMedID- 26058465 This study aimed to assess hbv reactivation and hepatitis occurrence in diffuse large b-cell lymphoma (dlbcl) patients with resolved hepatitis b receiving rituximab-containing chemotherapy compared with hbsag-negative/hbcab-negative patients to identify risk factors for hbv reactivation and hepatitis occurrence and to analyze whether hbv reactivation and hepatitis affect the survival of dlbcl patients with resolved hepatitis b.
PubMedID- 20837949 Prospective analysis of hepatitis b virus reactivation in patients with diffuse large b-cell lymphoma after rituximab combination chemotherapy.
PubMedID- 22029053 "prospective analysis of hepatitis b virus reactivation in patients with diffuse large b-cell lymphoma after rituximab combination chemotherapy".
PubMedID- 25848698 We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large b-cell lymphoma (dlbcl) patients with hepatitis b virus (hbv) infection and compare with those without hbv infection.
PubMedID- 25514302 Conclusions and relevance: among patients seropositive for the hepatitis b surface antigen with diffuse large b-cell lymphoma undergoing r-chop chemotherapy, the addition of entecavir compared with lamivudine resulted in a lower incidence of hbv-related hepatitis and hbv reactivation.

Page: 1